中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 11
Nov.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(11): 2659-2662

The role of competitive endogenous RNA in the development of cholangiocarcinoma

DOI: 10.3969/j.issn.1001-5256.2022.11.044

  • Department of Hepatobiliary, Pancreatic and Splenic Surgery, The Affiliated Yantai Hospital of Binzhou Medical University, Yantai, Shandong 264100, China

More Information
  • Corresponding author: WEI Yong, weiyonglancet@163.com(ORCID: 0000-0002-3279-9465)
  • Received Date: 2022-03-13
  • Accepted Date: 2022-05-15
  • Published Date: 2022-11-20
    Abstract
  • Cholangiocarcinoma is a highly malignant tumor with a poor prognosis, limited treatment options, and complicated pathogenesis. Competitive endogenous RNA is a kind of transcripts that can competitively bind miRNA, including long non-coding RNA and circular RNA. Competitive endogenous RNA is known to be involved in a variety of tumors. It can modulate the occurrence and development of cholangiocarcinoma by regulating the biological behavior, cell metabolism, inflammatory process and epithelial-mesenchymal transition of cholangiocarcinoma cells. Here we review recent research progress on the role of long non-coding RNA and circular RNA in cholangiocarcinoma to help better understand the pathogenesis of cholangiocarcinoma.

     

    • FullText(HTML)
  • loading
    • References(31)
  • [1]
    YU Y, CHEN Q, ZHANG X, et al. Long noncoding RNA ANRIL promotes the malignant progression of cholangiocarcinoma by epigenetically repressing ERRFI1 expression[J]. Cancer Sci, 2020, 111(7): 2297-2309. DOI: 10.1111/cas.14447.
    [2]
    DU C, LI DQ, LI N, et al. DDX5 promotes gastric cancer cell proliferation in vitro and in vivo through mTOR signaling pathway[J]. Sci Rep, 2017, 7: 42876. DOI: 10.1038/srep42876.
    [3]
    XUE Y, JIA X, LI L, et al. DDX5 promotes hepatocellular carcinoma tumorigenesis via Akt signaling pathway[J]. Biochem Biophys Res Commun, 2018, 503(4): 2885-2891. DOI: 10.1016/j.bbrc.2018.08.063.
    [4]
    ZHANG M, WENG W, ZHANG Q, et al. The lncRNA NEAT1 activates Wnt/β-catenin signaling and promotes colorectal cancer progression via interacting with DDX5[J]. J Hematol Oncol, 2018, 11(1): 113. DOI: 10.1186/s13045-018-0656-7.
    [5]
    CONTAT C, ANCEY PB, ZANGGER N, et al. Combined deletion of Glut1 and Glut3 impairs lung adenocarcinoma growth[J]. Elife, 2020, 9. DOI: 10.7554/eLife.53618.
    [6]
    SUN Q, GONG X, WU J, et al. Effect of lncRNA PVT1/miR186/KLF5 axis on the occurrence and progression of cholangiocarcinoma[J]. Biomed Res Int, 2021, 2021: 8893652. DOI: 10.1155/2021/8893652.
    [7]
    TU J, WU F, CHEN L, et al. Long non-coding RNA PCAT6 Induces M2 polarization of macrophages in cholangiocarcinoma via modulating miR-326 and RhoA-ROCK signaling pathway[J]. Front Oncol, 2020, 10: 605877. DOI: 10.3389/fonc.2020.605877.
    [8]
    HUANG L, JIANG X, KANG P, et al. Long non-coding RNA NNT-AS1 functions as an oncogenic gene through modulating miR-485/BCL9 in cholangiocarcinoma[J]. Cancer Manag Res, 2019, 11: 7739-7749. DOI: 10.2147/CMAR.S207801.
    [9]
    LIN H, YANG L, TIAN F, et al. Up-regulated LncRNA-ATB regulates the growth and metastasis of cholangiocarcinoma via miR-200c signals[J]. Onco Targets Ther, 2019, 12: 7561-7571. DOI: 10.2147/OTT.S217676.
    [10]
    YU Y, ZHANG M, LIU J, et al. Long non-coding RNA PVT1 promotes cell proliferation and migration by silencing ANGPTL4 expression in cholangiocarcinoma[J]. Mol Ther Nucleic Acids, 2018, 13: 503-513. DOI: 10.1016/j.omtn.2018.10.001.
    [11]
    XU Y, YAO Y, LENG K, et al. Long non-coding RNA UCA1 indicates an unfavorable prognosis and promotes tumorigenesis via regulating AKT/GSK-3β signaling pathway in cholangiocarcinoma[J]. Oncotarget, 2017, 8(56): 96203-96214. DOI: 10.18632/oncotarget.21884.
    [12]
    YANG L, DAI F, TANG L, et al. Macrophage differentiation induced by PMA is mediated by activation of RhoA/ROCK signaling[J]. J Toxicol Sci, 2017, 42(6): 763-771. DOI: 10.2131/jts.42.763.
    [13]
    GU Y, ZHU Z, PEI H, et al. Long non-coding RNA NNT-AS1 promotes cholangiocarcinoma cells proliferation and epithelial-to-mesenchymal transition through down-regulating miR-203[J]. Aging (Albany NY), 2020, 12(3): 2333-2346. DOI: 10.18632/aging.102747.
    [14]
    XU Y, YAO Y, JIANG X, et al. SP1-induced upregulation of lncRNA SPRY4-IT1 exerts oncogenic properties by scaffolding EZH2/LSD1/DNMT1 and sponging miR-101-3p in cholangiocarcinoma[J]. J Exp Clin Cancer Res, 2018, 37(1): 81. DOI: 10.1186/s13046-018-0747-x.
    [15]
    LI Z, JIANG X, HUANG L, et al. Up-regulation of ZFAS1 indicates dismal prognosis for cholangiocarcinoma and promotes proliferation and metastasis by modulating USF1 via miR-296-5p[J]. J Cell Mol Med, 2019, 23(12): 8258-8268. DOI: 10.1111/jcmm.14698.
    [16]
    WANG H, WANG L, TANG L, et al. Long noncoding RNA SNHG6 promotes proliferation and angiogenesis of cholangiocarcinoma cells through sponging miR-101-3p and activation of E2F8[J]. J Cancer, 2020, 11(10): 3002-3012. DOI: 10.7150/jca.40592.
    [17]
    LV Y, XIAO J, LIU J, et al. E2F8 is a potential therapeutic target for hepatocellular carcinoma[J]. J Cancer, 2017, 8(7): 1205-1213. DOI: 10.7150/jca.18255.
    [18]
    ROY S, GLASER S, CHAKRABORTY S. Inflammation and progression of cholangiocarcinoma: role of angiogenic and lymphangiogenic mechanisms[J]. Front Med (Lausanne), 2019, 6: 293. DOI: 10.3389/fmed.2019.00293.
    [19]
    LI X, LIU R, WANG Y, et al. Cholangiocyte-derived exosomal lncRNA H19 promotes macrophage activation and hepatic inflammation under cholestatic conditions[J]. Cells, 2020, 9(1): 190. DOI: 10.3390/cells9010190.
    [20]
    WANG WT, YE H, WEI PP, et al. LncRNAs H19 and HULC, activated by oxidative stress, promote cell migration and invasion in cholangiocarcinoma through a ceRNA manner[J]. J Hematol Oncol, 2016, 9(1): 117. DOI: 10.1186/s13045-016-0348-0.
    [21]
    KRISTENSEN LS, ANDERSEN MS, STAGSTED L, et al. The biogenesis, biology and characterization of circular RNAs[J]. Nat Rev Genet, 2019, 20(11): 675-691. DOI: 10.1038/s41576-019-0158-7.
    [22]
    TANG Q, HANN SS. Biological roles and mechanisms of circular RNA in human cancers[J]. Onco Targets Ther, 2020, 13: 2067-2092. DOI: 10.2147/OTT.S233672.
    [23]
    LI D, TANG Z, GAO Z, et al. Circular RNA CDR1as exerts oncogenic properties partially through regulating MicroRNA 641 in cholangiocarcinoma[J]. Mol Cell Biol, 2020, 40(15): e00042-20. DOI: 10.1128/MCB.00042-20.
    [24]
    XU Y, GAO P, WANG Z, et al. Circ-LAMP1 contributes to the growth and metastasis of cholangiocarcinoma via miR-556-5p and miR-567 mediated YY1 activation[J]. J Cell Mol Med, 2021, 25(7): 3226-3238. DOI: 10.1111/jcmm.16392.
    [25]
    ZHAO X, ZHANG X, ZHANG Z, et al. Comprehensive circular RNA expression profiling constructs a ceRNA network and identifies hsa_circ_0000673 as a novel oncogene in distal cholangiocarcinoma[J]. Aging (Albany NY), 2020, 12(22): 23251-23274. DOI: 10.18632/aging.104099.
    [26]
    XU Y, YAO Y, LIU Y, et al. Elevation of circular RNA circ_0005230 facilitates cell growth and metastasis via sponging miR-1238 and miR-1299 in cholangiocarcinoma[J]. Aging (Albany NY), 2019, 11(7): 1907-1917. DOI: 10.18632/aging.101872.
    [27]
    TU J, CHEN W, ZHENG L, et al. Circular RNA Circ0021205 promotes cholangiocarcinoma progression through mir-204-5p/RAB22A axis[J]. Front Cell Dev Biol, 2021, 9: 653207. DOI: 10.3389/fcell.2021.653207.
    [28]
    YOU J, WANG X. Circ_HIPK3 knockdown inhibits cell proliferation, migration and invasion of cholangiocarcinoma partly via mediating the miR-148a-3p/ULK1 pathway[J]. Cancer Manag Res, 2021, 13: 3827-3839. DOI: 10.2147/CMAR.S293823.
    [29]
    SU Y, YU T, WANG Y, et al. Circular RNA circDNM3OS functions as a miR-145-5p sponge to accelerate cholangiocarcinoma growth and glutamine metabolism by upregulating MORC2[J]. Onco Targets Ther, 2021, 14: 1117-1129. DOI: 10.2147/OTT.S289241.
    [30]
    HENSLEY CT, WASTI AT, DEBERARDINIS RJ. Glutamine and cancer: cell biology, physiology, and clinical opportunities[J]. J Clin Invest, 2013, 123(9): 3678-3684. DOI: 10.1172/JCI69600.
    [31]
    CHEN S, CHEN Z, LI Z, et al. Tumor-associated macrophages promote cholangiocarcinoma progression via exosomal Circ_0020256[J]. Cell Death Dis, 2022, 13(1): 94. DOI: 10.1038/s41419-022-04534-0.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (253) PDF downloads(20) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return